A comment on the Sun et al trial 'Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial'

Sun et al published an exciting randomized control trial in the November issue investigating the role of adjuvant intensity-modulated radiotherapy (IMRT) in patients after resected hepatocellular carcinoma(HCC) with portal vein tumor thrombus(PVTT)[1]. It is a relevant study targeting disease with a dismal prognosis especially when it presents with PVTT[2]. The authors did a commendable job summarizing their data and findings. However, after analyzing the trial and the results, we are curious about a few aspects which could clarify the findings of the study.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Letter to the Editor Source Type: research